Brodalumab meets all primary and all key secondary endpoints Meets primary endpoint of superiority to Stelara® (ustekinumab) in achieving total skin clearance (PASI 100) Meets co-primary endpoints against placebo
AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from the company’s growing inflammation and autoimmunity portfolio at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts, 14-19 November 2014.
More than 15 abstracts will be featured at the ACR meeting, providing evidence of the depth and continued progress
AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalised lipodystrophy.
Myalept is the first and only product approved in the US for the treatment of generalised lipodystrophy and it h
Intäkterna under tredje kvartalet uppgick till 6 542 MUSD, en ökning med 5 % i fasta valutakurser (CER), det tredje kvartalet i följd med intäktstillväxt, med starkt bidrag från tillväxtplattformarna som pådrivande faktor. Intäkterna under niomånadersperioden ökade med 4 % (Q3 2013: 6 250 MUSD).
Rörelseresultatet för kärnverksamheten minskade med 9 % till 1 770 MUSD.
Vinsten per aktie för kä
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development, LLC (“Janssen”) today announced that they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton’s tyrosine kinase inhibitor, co-developed by Pharmacyclic
Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue.
Definiens’ proprietary Cognition Network Tech
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company.
As previously announced, the business combination gives AstraZeneca ownership of the rights for the development and commercialisation of Almirall’s proprietary respiratory business, including rights to revenues from Almirall’s existing partnershi
First US approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release
AstraZeneca har idag lanserat ett program som syftar till att angripa problemen med högt blodtryck i Afrika. Healthy Heart Africa har utformats i konsultation och samarbete med icke-statliga organisationer (NGO’s) och lokala organisationer, internationella organisationer, hälsoexperter och myndigheter för att stödja de lokala hälso- och sjukvårdssystemen genom att öka medvetenheten om symptomen oc
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, f
Vid två nationella diabetessymposier arrangerade av AstraZeneca diskuterades det senaste inom diabetesvården i allmänhet och läkemedel i synnerhet. I takt med att fler behandlingsalternativ för typ 2-diabetes blir tillgängliga ökar behovet av att hitta bästa behandlingsalternativ för varje enskild patient. Hur kan nya lälmedel bidra?
